The Regulatory Academy Blog
Office Hours
The questions every cohort asks — about the career, the craft, and the first job — answered properly, in writing, by someone who does the work.
The Blog
Asked in Office Hours.
Answered in Writing.
Short, practical essays on careers and craft in regulatory affairs — the questions every cohort asks, answered properly once.
163 essays
-
Oct 212026
Moving From Medical Writing Into Regulatory Affairs
Medical writers already know how to read the data regulators ask for — here is what changes, and what transfers, when you move into regulatory affairs itself.
-
Oct 212026
What an FDA Drug Shortage Notice Actually Requires
Section 506C gives FDA a six-month warning before certain drugs disappear — here is what triggers the notice, who has to send it, and what FDA does with it.
-
Oct 212026
What a Humanitarian Device Exemption Actually Requires
A Humanitarian Device Exemption trades effectiveness proof for a population cap and IRB oversight — what that trade actually requires in practice.
-
Oct 202026
Generalist or Specialist: Choosing Your Regulatory Path
Every regulatory career eventually forks between depth in one pathway and breadth across many — here is how that choice gets made, and sometimes unmade.
-
Oct 202026
What to Do When Your Predicate Device Gets Recalled
A recalled predicate doesn’t erase a clearance already granted, but it changes what you can lean on next time — here is how FDA’s own guidance treats it.
-
Oct 202026
510(k) Summary or Statement: What You’re Committing To
Every 510(k) must include a public summary or a statement promising the data on request — the choice carries consequences most submitters never weigh.
-
Oct 192026
How to Read a Field Alert Report
A Field Alert Report runs on a three-working-day clock that starts when you learn of a problem, not when you confirm it — the mistake that trips people up.
-
Oct 192026
Moving From FDA Into Industry Regulatory Affairs
Leaving FDA for industry regulatory affairs means learning a new side of the same system, under real limits on what you can touch and who you can call.
-
Oct 192026
What FDA Establishment Registration Actually Requires
Registering a device establishment, and listing each device, are real legal deadlines — and by FDA’s own rule, neither one is an approval or endorsement.
-
Oct 112026
Postmarketing Requirement vs. Postmarketing Commitment
One label is a legal mandate with real penalties attached; the other is a written promise FDA enforces differently. Knowing which one you are reading matters.
-
Oct 92026
How to Estimate a Regulatory Submission Timeline
A 510(k)’s “90 days” and a PMA’s “180 days” are not the same kind of promise. Here is how FDA’s review clocks actually work, and how to turn one into a plan.
-
Oct 82026
How to Read a Citizen Petition
A citizen petition can flag a genuine safety problem, or try to stall a rival’s approval. FDA’s own rule for telling the two apart runs on a hard 150-day clock.
-
Oct 82026
How to Read an FDA Drug Approval Letter
An approval letter isn’t the finish line it feels like. Here’s what FDA is actually certifying under 21 CFR 314.105 and 601.4 — and what isn’t settled yet.
-
Oct 82026
How Regulatory Affairs Works With Manufacturing
A routine-looking manufacturing change can trigger a new 510(k) or NDA supplement. The relationship works when regulatory affairs catches that early.
-
Oct 72026
Managing Up When Your Manager Isn’t Regulatory
When your manager has never worked in regulatory, the job isn’t explaining the science. It’s translating a judgment call into something they can act on.
-
Oct 72026
How to Read a Special Protocol Assessment
A Special Protocol Assessment locks in your Phase 3 trial design before you run it. Here’s what FDA is actually agreeing to, and what it isn’t.
-
Oct 72026
How to Read a 505(b)(2) Application
A 505(b)(2) application leans on someone else’s safety data instead of your own. 21 CFR 314.54 spells out exactly what that borrowing costs in return.
-
Oct 62026
Moving From a CRO Into Sponsor-Side Regulatory Affairs
A CRO’s obligations end at the contract. In-house, regulatory affairs owns the file indefinitely — 21 CFR 312.52 only transfers what the agreement describes.
-
Oct 62026
What Orphan Drug Designation Actually Changes
Designation isn’t a fast track to approval. It’s a prevalence test under 21 CFR Part 316 that changes what a sponsor is entitled to, not FDA’s evidence bar.
-
Oct 62026
How to Read a Clinical Study Report
A clinical study report isn’t a results memo with tables attached — ICH E3 structures it as an argument a reviewer can evaluate without re-deriving the trial.
-
Oct 52026
How to Read a Periodic Safety Update Report
A PSUR isn’t an annual report you file and forget. Under MDR Article 86 it has to tie post-market data to a benefit-risk conclusion a notified body reviews.
-
Oct 42026
How to Work With a Notified Body Under EU MDR
A notified body isn’t an auditor you pass once. Under MDR it holds ongoing authority over your technical file — including the right to show up unannounced.
-
Oct 42026
Owning Your First Submission End to End
The first time you own a submission, the hard part isn’t the writing. It’s becoming the person every other function waits on — and learns to trust.
-
Oct 42026
How to Read a Form FDA 1572
A Form FDA 1572 isn’t intake paperwork. Signing it commits an investigator to the protocol, the IRB, and FDA’s recordkeeping rules directly.
-
Oct 22026
How to Read a Clinical Evaluation Report
A Clinical Evaluation Report isn’t a literature summary. EU MDR requires it to conclude whether the clinical evidence actually supports the device.
-
Oct 22026
Giving Feedback to Someone You Manage
Feedback from a manager carries weight a peer’s never does, which is exactly why vague, rare, or conflict-avoidant feedback does more damage than none at all.
-
Oct 22026
How to Read a Master File Letter of Authorization
A Letter of Authorization doesn’t hand over a Drug Master File — it tells FDA exactly what in someone else’s confidential file you may reference, and no more.
-
Oct 12026
How to Read an EUA Letter of Authorization
An Emergency Use Authorization is not an approval or a clearance — it is a time-limited, revocable pathway with its own statutory criteria to meet.
-
Oct 12026
Moving From Clinical Affairs Into Regulatory Affairs
Clinical affairs and regulatory affairs sit close together on an org chart, but the job itself changes more than the title suggests it would.
-
Oct 12026
How to Read a PMA Supplement
Not every change to an approved PMA device needs a new application. A supplement tells FDA what changed, and its type sets how much review is coming.
-
Sep 302026
How to Read an FDA Compliance Program Guidance Manual
FDA investigators work from a public Compliance Program Guidance Manual for your inspection type — reading it first tells you what they’ll actually check.
-
Sep 302026
How to Handle a Layoff or Reorg in Regulatory Affairs
A layoff or reorg is disorienting, especially when regulatory affairs is a company’s only seat — what to check first, and how to keep moving forward.
-
Sep 302026
How to Read an FDA Certificate to Foreign Government
A Certificate to Foreign Government tells an importing country your product is legally marketed in the US — what it actually verifies, and what it doesn’t.
-
Sep 292026
How to Build a Design Control Traceability Matrix
A traceability matrix links every user need to a design input, output, and test record — what belongs in one, and why reviewers ask for it before anything else.
-
Sep 292026
How to Work With a Regulatory Affairs Recruiter
A recruiter is paid to fill a role, not manage your career — knowing which kind you’re talking to, and what to tell them early, makes the relationship useful.
-
Sep 292026
How to Submit a Public Comment on FDA Draft Guidance
Anyone can comment on FDA draft guidance, not just regulated companies — what makes a comment worth reading, and the mechanics of actually filing one.
-
Sep 282026
How to Read an FDA Warning Letter Close-Out Letter
A close-out letter tells the public FDA considers a warning letter resolved — it is not proof of full compliance, and reading it as one is the mistake to avoid.
-
Sep 282026
How to Interview a Regulatory Affairs Candidate
Interviewing a regulatory affairs candidate well means testing judgment under ambiguity, not a resume — what to ask, and what the answers actually reveal.
-
Sep 282026
How to Write a Regulatory Affairs Cover Letter
A regulatory affairs cover letter earns attention by naming one decision you made, not by restating your resume — what actually belongs in the three paragraphs.
-
Sep 272026
How to Read an FDA Consent Decree
A consent decree is a federal court order a company agrees to, not an admission of guilt — here is what its terms actually commit a firm to do.
-
Sep 272026
How to Read an IRB Approval Letter
An IRB approval letter authorizes one protocol and consent version, not a study in general, and it expires on its own if continuing review lapses.
-
Sep 272026
Moving From Regulatory Affairs Into Medical Writing
Regulatory affairs already trains the skill medical writing pays for: writing to evidence. What transfers, what doesn’t, and how to test it first.
-
Sep 262026
Regulatory Strategy vs. Regulatory Operations
Strategy sets the pathway and argues it to FDA; operations builds and files the submission that carries it. Picking a lane shapes years of your career.
-
Sep 262026
How Regulatory Affairs Works With Legal
Regulatory reads a claim against what was cleared; legal reads it against what could be sued over. The overlap is real, and so is the gap between them.
-
Sep 262026
How to Read a Letter-to-File Decision
Most device changes never reach FDA — a manufacturer decides internally, in writing, whether a change needs a new 510(k) or just a documented rationale.
-
Sep 252026
How to Know When to Leave a Regulatory Affairs Job
Burnout, a bad manager, and a stalled career look similar from the inside. Separating them tells you whether to fix the job, wait it out, or start looking.
-
Sep 252026
How Regulatory Affairs Works With Marketing
Marketing wants a claim that sells; regulatory confirms it says only what was cleared or approved — catching the gap early is cheaper than after launch.
-
Sep 252026
How to Read a PMA Annual Report
A PMA doesn’t end at approval — the periodic report is where a manufacturer shows the device still matches what FDA approved, before an inspector notices drift.
-
Sep 242026
When You Disagree With Your Manager’s Strategy
Most of these are a risk-appetite difference, not a rules violation — how you handle being overruled shapes whether your manager wants your view next time.
-
Sep 242026
How to Read a Device Master Record
The DMR isn’t the design history file — it’s the current, approved recipe a manufacturing line builds from, and it protects you only if it stays current.
-
Sep 242026
How to Read an FDA Clinical Hold Letter
A clinical hold isn’t a rejection — it’s an order to stop specific activities until specific deficiencies are resolved. Reading which ones is the job.
-
Sep 232026
Is a Master’s in Regulatory Affairs Worth It?
It isn’t a credential any agency requires or recognizes. Who actually gets value from the degree, and when real submission experience is the better investment.
-
Sep 232026
How Regulatory Affairs Works With Clinical
Regulatory keeps the IND current; clinical runs the trial. Here’s where that division of labor sits, and where a missed handoff turns into a reportable problem.
-
Sep 232026
How to Read an IND Application
An IND application isn’t a safety file — it’s an argument that the nonclinical data support a specific dose, protocol, and population. Here’s what to check.
-
Sep 222026
Moving From Regulatory Affairs Into Quality
Regulatory affairs builds the argument; quality verifies the evidence and owns the system that produces it. What transfers when you move, and what doesn’t.
-
Sep 222026
How to Read an IND Annual Report
An IND annual report isn’t a bigger safety report — it’s the once-a-year synthesis of a program, and the investigational plan repays the closest reading.
-
Sep 202026
How to Onboard Yourself When Nobody Else Will
Nobody handed you a plan? Read the regulation itself, not just the SOP that cites it, and map who actually knows what before you wait for someone else to.
-
Sep 182026
How to Mentor Someone Newer Than You in Regulatory Affairs
Being reachable isn’t the same as being useful. What actually helps a junior colleague grow is showing your reasoning, not just handing over your answer.
-
Sep 182026
How to Read an IND Safety Report
An IND safety report only applies to events that are serious, unexpected, and plausibly drug-caused — not every adverse event qualifies. Here’s how it works.
-
Sep 182026
How to Read a REMS
A REMS attaches real restrictions to how a drug gets prescribed or dispensed — not every element applies to every drug. Here’s what to check first.
-
Sep 172026
How Regulatory Affairs Works With Quality
Regulatory and quality run on the same records but answer different questions. Here’s where that split falls, and where it breaks without a shared file.
-
Sep 172026
How to Read a CAPA
A CAPA has to show a correction addressed the actual cause, not just the symptom, and that someone verified it worked. Here’s what a defensible one contains.
-
Sep 172026
How to Read a Biocompatibility Evaluation Report
A biocompatibility file isn’t a checklist of passed tests — it’s an argument for why those were the right tests for this device. Here’s how to read one.
-
Sep 162026
How to Read a Complaint File
A complaint file has to do two things: capture what the customer actually said, and show your reasoning for whether it was reportable. Here’s how to read one.
-
Sep 162026
How to Advance in Regulatory Affairs Without Managing
Staying an individual contributor doesn’t mean staying in place. What actually has to change for the next title to make sense with no headcount to point to.
-
Sep 152026
How to Read a Device Cybersecurity Submission
Cybersecurity documentation is now required in many device submissions. Here’s what the package has to show, and what a thin one looks like to a reviewer.
-
Sep 152026
How to Read a Risk Management File
A risk management file is supposed to prove every hazard traces to a control that actually works. Here’s what holds that chain together, and what breaks it.
-
Sep 152026
How to Onboard a New Regulatory Affairs Hire
Onboarding a new regulatory hire well means compressing months of context into weeks without dumping it all on day one. Here’s what to hand them, and when.
-
Sep 142026
How to Write a Submission Handoff Someone Else Can Use
A regulatory handoff is the last artifact you produce in a role. What needs to be in it, and why most fail the person who inherits the work.
-
Sep 142026
How to Read a Human Factors Validation Report
A validation report is supposed to prove real users can operate the device safely. What it has to connect, and what a thin one looks like.
-
Sep 142026
How to Evaluate a Regulatory Affairs Team Before You Join
An offer letter tells you the salary and the title. It doesn’t tell you whether the team has the standing to let you do the job well.
-
Sep 132026
Building a Body of Work When It’s All Confidential
You can’t show anyone the submissions you actually worked on. What still proves you can do the job — and how to talk about work you can’t describe in detail.
-
Sep 132026
How to Read a PMA Refuse-to-File Decision
A PMA can be refused before FDA ever reviews the science. What triggers a Refuse-to-File decision, how it differs from a 510(k) RTA, and what to do with one.
-
Sep 132026
How to Read Your FDA Pre-Submission Meeting Minutes
The meeting itself is informal; the minutes are the record. What FDA’s Q-Submission meeting minutes actually commit you to, and how to read them before you act.
-
Sep 122026
What EU MDR Requires That FDA Doesn’t
The EU MDR runs on a different reviewer, a different accountability structure, and a different relationship to clinical evidence than the FDA’s device pathways.
-
Sep 122026
How to Read a Design History File
A Design History File isn’t one document but a chain of evidence — what it has to prove, and how to read it the way an FDA investigator or a new hire would.
-
Sep 122026
How to Change Companies in Regulatory Affairs
Pathway judgment travels between employers. Process and relationships don’t. What to expect when you change companies, and how to leave well.
-
Sep 112026
What the QMSR Actually Changes
The Quality Management System Regulation replaced 21 CFR 820’s old language with ISO 13485:2016 by reference. What changed, and what stayed the same.
-
Sep 112026
How to Read a PMA Summary of Safety and Effectiveness Data
A PMA’s Summary of Safety and Effectiveness Data is FDA’s public record of why a device was approved — read it well, and know what it leaves out.
-
Sep 112026
How to Build the Case for a Promotion
A promotion in regulatory affairs rarely arrives on schedule. What to track between reviews, how to learn what the next level requires, and how to ask.
-
Sep 22026
How to Review a Colleague’s Regulatory Draft
A colleague’s draft deserves more than “looks good.” What a useful reviewer actually checks, and how to write comments the author can act on.
-
Sep 12026
How to Brief a Team on a New FDA Requirement
A new FDA requirement means nothing to your team until you translate it into what changes for their program, by when, and who has to act on it.
-
Sep 12026
How to Run a Submission Readiness Review
A readiness review is the last honest look before you submit, not a repeat of the RTA checklist. What it actually checks, and who belongs in the room.
-
Sep 12026
How to Push Back on a Launch Timeline You Didn’t Set
Regulatory doesn’t set FDA’s review clock, but pretending the whole timeline is out of your hands wastes your credibility. What to say instead.
-
Aug 312026
How to Read a Federal Register Notice
A Federal Register notice is not the regulation itself, and reading it like one wastes time. Where to look first, and what a docket number unlocks.
-
Aug 302026
What Breakthrough Device Designation Actually Changes
Breakthrough Devices Program designation buys FDA’s attention and priority review, not a lower bar for clearance. What actually changes, and what doesn’t.
-
Aug 292026
Being the Only Regulatory Voice in the Room
Being the only regulatory voice in a fast-moving room means separating what’s required from what’s your call. How to hold that line without losing the room.
-
Aug 292026
Writing an Indications for Use Statement You Can Defend
An indications for use statement quietly sets the boundary of your 510(k). How to write one your testing actually supports, and defend it after clearance.
-
Aug 292026
How to Read an FDA Advisory Committee Transcript
An advisory committee’s vote is FDA’s input, not its decision. How to read the transcript for the concerns and phrasing most likely to shape what happens next.
-
Aug 282026
Handling a Regulatory Decision You Disagree With
Disagreeing with a regulatory determination is normal; how you raise it shapes your credibility. A practical way to make your case, then know when to let it go.
-
Aug 282026
Your First Regulatory Affairs Performance Review
Your first performance review rewards work that’s easy to miss from outside the function. How to document what you decided, before the conversation happens.
-
Aug 282026
Responding to an FDA Additional Information Request
An FDA Additional Information request pauses your submission, not your case. How to answer exactly what’s asked without reopening what’s already settled.
-
Aug 272026
How to Run a Study Group for the RAC Exam
Studying alone for the RAC exam works until it doesn’t. How to structure a small peer study group so it forces retrieval and exposes blind spots.
-
Aug 262026
Building a Working File of Predicate and Precedent Devices
Bookmarking 510(k) summaries isn’t the same as building expertise. How to keep a working file of predicate devices that gets more useful every time you use it.
-
Aug 262026
Teaching a Colleague What Regulatory Affairs Actually Does
A short, honest session on what regulatory affairs actually owns changes how engineers and other colleagues work with you — far more than a lecture on the CFR.
-
Aug 262026
Giving a Regulatory Update Executives Will Actually Use
A status update that lists activity instead of decisions won’t get read twice. What a submission update should say, and what can wait for the next one.
-
Aug 252026
The First Regulatory Affairs Hire
What changes when you’re the only regulatory affairs person at a company, with no existing function, no playbook, and no one to calibrate against.
-
Aug 252026
How to Read an MDSAP Audit Report
A single MDSAP audit can satisfy five regulators at once. How the report is structured, how findings are graded, and what a clean one doesn’t tell you.
-
Aug 252026
How to Write a Response to an FDA Warning Letter
A warning letter response isn’t a corrective action plan with a cover page. What FDA is actually evaluating, and why the signature on it matters.
-
Aug 242026
How to Read an FDA Postmarket Surveillance Order
A postmarket surveillance order isn’t a penalty. It’s FDA requiring a study after clearance, tied to Section 522 — and what the order asks a manufacturer to do.
-
Aug 242026
How to Read an FDA Safety Communication
An FDA safety communication carries no legal force of its own. What one actually is, why FDA issues them, and how a practitioner should read one correctly.
-
Aug 242026
How to Work With a Regulatory Affairs Consultant
Hiring a regulatory consultant doesn’t move the responsibility off your desk. How to scope the engagement, and what a consultant can’t take off your plate.
-
Aug 232026
How to Read an FDA Establishment Inspection Report
A Form 483 lists what an investigator observed. The Establishment Inspection Report is FDA’s own narrative behind it, and getting one takes a records request.
-
Aug 232026
How to Read an FDA Not Substantially Equivalent Letter
An NSE letter doesn’t end a 510(k) pathway — it forecloses one predicate comparison. What the letter says, and the three ways forward after it.
-
Aug 232026
Startups vs. Established Companies in Regulatory Affairs
Neither path is inherently better for a regulatory affairs career — what changes is the pace, the mentorship, and how early you're trusted with real scope.
-
Aug 222026
Building expertise in one product area
Depth in one product area compounds faster than breadth ever does early on — what that actually means when you rarely get to choose the assignment.
-
Aug 222026
How to read an FDA 513(g) response
A 513(g) response tells you how FDA would classify a device — it is not a clearance, and reading it as one is the most common way this document gets misused.
-
Aug 222026
How to read an FDA import alert
An import alert puts a firm’s shipments on detention before they reach a review — what triggers one, how DWPE works, and how a listing actually gets removed.
-
Aug 212026
How to read an FDA advisory committee briefing
Before a panel votes, FDA and the sponsor each publish a briefing document — what the two documents contain, and where they tend to disagree.
-
Aug 212026
How to read an FDA notice of inspection
Form FDA 482 is what an investigator presents at your door under Section 704 of the FD&C Act — what it establishes, and what to do in the first hour.
-
Aug 212026
How to negotiate a regulatory affairs job offer
Compensation is usually fixed by the time an offer lands. Start date, level, relocation, and exam support often are not — what to ask for, and how to ask.
-
Aug 202026
The case for keeping a regulatory decision log
A running record of the small judgment calls you make is worth more than memory once an audit or a new hire needs to understand how you got there.
-
Aug 202026
How to get value from a regulatory affairs conference
The sessions matter less than the conversations. What a trade conference rewards is different from what an FDA public meeting or a paid course rewards.
-
Aug 192026
How to read an FDA inspection classification
A Form FDA 483 lists observations. The classification that follows — NAI, VAI, or OAI — is what actually determines whether the story ends there.
-
Aug 192026
How to write an FDA 483 response
A 483 response isn’t a form to fill out. It’s a technical document that shapes whether FDA classifies the inspection as VAI or moves toward a Warning Letter.
-
Aug 192026
How regulatory affairs works with R&D
Regulatory affairs earns influence with engineering by showing up during design, not just at the end. Design controls give both functions a shared language.
-
Aug 182026
How FDA decides which center reviews your product
Combination products don’t pick their own review center. A Request for Designation is how a sponsor gets a binding answer instead of a guess.
-
Aug 182026
Moving from individual contributor to RA manager
The judgment that made you a strong specialist doesn’t automatically transfer once you’re responsible for someone else’s. What actually changes.
-
Aug 182026
How to read an FDA Untitled Letter
An Untitled Letter cites a real violation, without the deadline and escalation language a warning letter carries. Reading the difference correctly matters.
-
Aug 172026
How to read a predetermined change control plan
FDA can pre-authorize a defined set of future device changes inside the original submission. What a change control plan promises, and where its authority stops.
-
Aug 172026
What changes when you consult in regulatory affairs
The regulatory reasoning barely changes moving from in-house to consulting. What shifts is who owns the client relationship, the deadline, and the outcome.
-
Aug 172026
How to read a device’s UDI record in GUDID
Every device carries a Unique Device Identifier, and FDA publishes what it means in a public database. What its two halves tell you, and what they don’t.
-
Aug 162026
How to read an FDA complete response letter
When FDA finishes reviewing a drug application and the answer isn’t yes, it sends a Complete Response Letter instead of an approval letter. What that letter is built to do, and why you’ll rarely read the document itself.
-
Aug 162026
How to read an FDA De Novo classification order
When a novel, low-to-moderate-risk device has no predicate to compare against, FDA can grant it market authorization directly. What the resulting order actually says, and what it means for the next sponsor who reads it.
-
Aug 162026
From the bench to regulatory affairs
A research background gives you real, useful skills for this work — just not always the ones people assume, and not without some translation. What actually transfers, and what you have to learn from scratch.
-
Aug 152026
How to get value from an FDA public meeting
Advisory committee meetings and public workshops are open to attend, and sometimes to speak at. What they’re actually for, and the difference between a public meeting and a conversation about your own submission.
-
Aug 152026
How to read FDA’s IDE regulations
Before a device reaches the market, someone has to decide it is safe enough to study on people first. What an Investigational Device Exemption actually requires, and who makes that call.
-
Aug 142026
How to read FDA’s RTA checklist
Before anyone reviews the substance of your 510(k), someone checks whether it’s complete enough to review at all. What that first pass actually looks for.
-
Aug 142026
How to read FDA’s eSTAR submission template
eSTAR isn’t just a form to fill out — its structure previews how a reviewer will work through your file, long before they open it.
-
Aug 142026
Building a work sample with no RA experience
You can’t point to a track record you don’t have yet. How to build something concrete that shows the judgment a hiring manager is actually screening for.
-
Aug 132026
The regulatory affairs career ladder, explained
Associate, specialist, manager — titles change, but what earns the next one is judgment, not tenure. What shifts at each rung, and how to tell you’re ready.
-
Aug 132026
How to prepare for an FDA pre-submission meeting
A Pre-Sub is one chance to get FDA’s read before you build the file. What to bring, what to ask, and how the feedback actually gets used.
-
Aug 132026
How to read an FDA product classification entry
Every cleared device carries a product code that unlocks its regulatory history. How to read a classification entry, and what each field tells you.
-
Aug 82026
How to choose a regulatory affairs certificate program
A certificate program’s landing page sells an outcome. Only the syllabus shows what you’ll actually learn — and whether it’s built for the job you want.
-
Aug 72026
How to read a medical device report
MAUDE is public and searchable, and a report in it is an allegation, not a finding. Read the coded fields as an index, not a diagnosis.
-
Aug 72026
How to read an FDA recall
A recall notice looks alarming and is almost always mundane. What the Class I, II, and III label is actually measuring — and what it isn’t.
-
Aug 72026
Continuing education in regulatory affairs
A credential earned once goes stale the moment the rule underneath it changes. The free channels, the tracking habit, and why training has to leave a record.
-
Aug 62026
How to write a regulatory rationale you can defend
A rationale isn’t finished when it reads well. It’s finished when it survives someone trying to take it apart.
-
Aug 62026
Moving from quality into regulatory affairs
A quality background covers more regulatory ground than the job title suggests — but the move asks for a skill quality work doesn’t train.
-
Aug 62026
How to read a regulatory affairs job posting
Regulatory affairs job postings use inconsistent titles and requirement lists. Here’s how to read one closely before you apply.
-
Aug 52026
How to build a regulatory intelligence habit
Tracking regulatory change is a habit built over a career, not a project you finish once and move on from.
-
Aug 52026
How to read a 510(k) summary
FDA publishes a public summary for every 510(k) clearance. Here’s what it can tell you, and what it leaves out.
-
Aug 52026
Your first 90 days in regulatory affairs
The first ninety days in a new regulatory affairs role are for orientation, not output.
-
Aug 42026
Getting value from a regulatory affairs course
Enrolling in a course is easy. Getting real value from it takes more deliberate effort than just showing up and taking notes.
-
Aug 32026
How to get a useful review of your draft
A draft no one but its author has read is not ready to submit. How to ask for a review that finds a real problem, instead of one that just signs off on it.
-
Aug 32026
How to study for the RAC exam
Deciding to sit for the RAC is one question. Studying for it is another — a routine built around scenarios and primary sources, not flashcards.
-
Aug 32026
How a regulation actually changes
A regulation does not change the moment an agency decides it should. The rulemaking process, and why the effective date is rarely the whole story.
-
Aug 22026
How to read a Form FDA 483
The observations on a 483 are an investigator’s judgment, not a verdict — and the response you write in the days after usually matters more than what is written on the form.
-
Aug 22026
How to read a recognized consensus standard
Citing a consensus standard from memory is not the same as checking what FDA’s recognition entry for it actually covers today. How to read one closely enough to know the difference.
-
Aug 22026
Building a professional network in regulatory affairs
A network built only during a job search reads exactly like what it is. How to build professional relationships in regulatory affairs starting with the people already in the room.
-
Aug 12026
How to explain a regulatory decision
The reasoning behind a regulatory call is usually sound. The explanation of it, to the colleague who was not in the room when it was made, often is not — and an unexplained decision gets re-argued indefinitely, whether or not it was right.
-
Aug 12026
How to read a regulation, not just the guidance
Guidance documents are the readable version, so most people learn FDA’s rules from them first. But guidance is a paraphrase of the agency’s current thinking — the regulation is the enforceable text, and reading it directly is a different, learnable skill.
-
Aug 12026
Finding a mentor in regulatory affairs
There is no residency or licensing exam that hands you regulatory judgment. Almost everyone good at this work learned the parts that matter most from someone who happened to be generous with their reasoning.
-
Jul 312026
Working with an FDA reviewer during a submission
The review clock does not stop for good manners, but a submission that moves is usually the one whose answers were anticipated rather than argued with. What actually happens once a submission is in review, and how practitioners work with FDA rather than around it.
-
Jul 312026
Writing a regulatory affairs resume from adjacent work
Almost nobody arrives at regulatory affairs holding a regulatory affairs degree. How to translate quality, clinical, technical-writing, or bench experience into a resume a regulatory hiring manager actually reads — without inventing experience you don’t have.
-
Jul 312026
A day in regulatory affairs — what the work looks like
No two days look alike, and anyone who tells you otherwise is describing a slow week. But the work reliably breaks into the same small set of categories — and it’s worth seeing that shape before you accept an offer, not after.
-
Jul 282026
Teaching yourself regulatory affairs — what actually works
No employer hands you a curriculum before you have the job. What self-directed study actually looks like when it works, and the two habits that quietly waste a year of it.
-
Jul 272026
Moving between devices and pharma in regulatory affairs
The FD&C Act covers both, and a device reviewer and a drug reviewer are trained to ask almost nothing alike. What carries over when you move between the two, and what you have to relearn from zero.
-
Jul 272026
How to read an FDA warning letter
The observations were never a secret — the company saw them first, at the inspection’s close. What changes at the warning-letter stage, and how practitioners read one for the pattern behind the citations.
-
Jul 272026
Is the RAC certification worth it?
RAPS’ own credential is the closest thing this profession has to a license — and it isn’t one. What the exam actually tests, what a year of study costs you, and who it’s really for.
-
Jul 232026
How to get into regulatory affairs — the honest map
No degree points straight at this profession, and almost every posting asks for experience you don’t have yet. The routes that actually produce first jobs — and the ones that quietly don’t.
-
Jul 232026
How to read an FDA guidance document
Guidance is not law — but reviewers read it as a map of their own expectations. How practitioners take a forty-page PDF apart in an hour, and what they write down.
-
Jul 232026
Your first regulatory interview — what they listen for
The questions are predictable; the listening is not. What interviewers are actually testing when they ask about a submission you have never run — and how to answer without bluffing.
Nothing matches that search.
One email a month. Worth opening.
New essays and new courses, in one short email each month. No sales sequence. Unsubscribe anytime.
From the newsroom
Learn it here. Watch it move there.
Regulatory News is our independent newsroom — every story sourced to the primary record, published the day it lands. These are the beats behind this lesson. RegulatoryNews.com →
- Other regulatorsTGA, PMDA, Health Canada, NMPA and the rest.
- DrugsPharmaceutical approvals, labels and pathways.
- Devices510(k)s, De Novos, PMAs and EU MDR.
- BiologicsBLAs, biosimilars and CHMP opinions.
- ClinicalTrials, INDs, holds and study design.
- Full archiveEvery story we have published, searchable.
Essays Start the Thought. Courses Finish It.
Office Hours answers the questions around the work. The courses teach the work itself — free, practitioner-written, and structured so each lesson builds on the last. Start with the 510(k).